SURMOUNT-1 & SURMOUNT-4 data

Tirzepatide Plateau: Why the Weight-Loss Curve Flattens

📄 9 PubMed citations

A plateau is the expected shape of the curve on tirzepatide. Here is when it showed up in the trials, how much loss came after it, and what happened to people who stopped.

Where to buy · affiliate link
Tirzepatide 30 mglisted as GLP-2 TZ at Veratis$95

Code HIGHPEPTIDES takes 15% off at checkout: $80.75

Third-party COA on every lotIn stockShips in the lower 48, $15 standard
Buy tirzepatide at Veratis →

Affiliate link: HighPeptides earns a commission on orders. Research use only. Educational content, not medical advice.

🔬 A question that keeps coming up on X: does tirzepatide stop working around week 40? The numbers people quote (about 21% loss by week 36, another 5.5% over the next year, 14% regain after switching to placebo) come from SURMOUNT-4 and are accurate. What they describe is a slowdown, not a stop. We built this page from the published trial papers plus three post hoc analyses of them, and we flag where the evidence runs thin.
36.1 wks
Median time to plateau, BMI class II and III (SURMOUNT-1 post hoc)
5.5%
Further loss from week 36 to 88 when tirzepatide was continued (SURMOUNT-4)
14%
Weight regained from week 36 to 88 after switching to placebo (SURMOUNT-4)

Still logging injections in your Notes app?

A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.

Stacking compounds? Check interactions first →

Build your tracker →

Why does tirzepatide weight loss slow down?

🍽️
Appetite pushes back

In a 52-week study that estimated energy intake with a mathematical model from body-weight changes during drug-driven weight loss, each kilogram lost raised eating by about 100 kcal per day above baseline, more than three times the drop in energy expenditure (PMID 27804272). That study used canagliflozin, not tirzepatide, so treat it as the general physiology of a plateau rather than a tirzepatide-specific number.

📉
"Plateau" has a defined meaning

The Lilly post hoc analysis defined a plateau as less than 5% weight change over a 12-week window and every 12-week window after it (PMID 39800653). Weight can still drift down inside that definition, and the authors note that loss at the plateau was slightly lower than the end-of-study loss.

💉
Dose timing shapes the curve

SURMOUNT-1, the main obesity trial, gave tirzepatide once weekly with a 20-week dose escalation (PMID 35658024). In the post hoc analysis, people on 10 or 15 mg, younger people, and women were more likely to reach their plateau later (PMID 39800653).

⚖️
Starting weight moves the date

Median time to plateau was 24.3 weeks for people starting in the overweight range and 36.1 weeks for BMI class II and III (PMID 39800653). People with a higher starting BMI took longer to reach the plateau.

What the Data Shows

Overweight (BMI 27 to under 30)
Median time to plateau, SURMOUNT-1
24.3 wks
Obesity class I
Median time to plateau, SURMOUNT-1
26.0 wks
Obesity class II
Median time to plateau, SURMOUNT-1
36.1 wks
Obesity class III
Median time to plateau, SURMOUNT-1
36.1 wks

After week 36: stay on it or stop?

SURMOUNT-4 put everyone on tirzepatide (10 or 15 mg, the highest dose each person tolerated) for 36 weeks, then randomized 670 people to keep going or switch to placebo for 52 more weeks. This is the trial behind the "21% by week 36, 5.5% more, 14% regain" numbers that circulate on X, and those figures match the paper (PMID 38078870).

SURMOUNT-4 phaseStayed on tirzepatideSwitched to placebo
Weeks 0 to 36 (everyone on open-label tirzepatide)Mean loss 20.9% for those who completed the lead-inSame pooled 20.9% lead-in (the two arms split only at week 36)
Weeks 36 to 88-5.5% (further loss)+14.0% (regain)
Weeks 0 to 88, overall-25.3%-9.9%
Kept at least 80% of the lead-in loss at week 8889.5%16.6%

Staying on the drug after week 36 still produced a further 5.5% loss, not a reversal. Stopping is what reversed the curve.

Where the curve flattened in each SURMOUNT trial

Different populations land at different heights. People with type 2 diabetes lost less in SURMOUNT-2 than people without diabetes did in SURMOUNT-1, so compare yourself with the right row.

TrialWho was in itMean weight change on tirzepatide
SURMOUNT-1, 72 weeksObesity or overweight, no diabetes-15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo
SURMOUNT-1, 176 weeksSubgroup with obesity and prediabetes-12.3% (5 mg), -18.7% (10 mg), -19.7% (15 mg) vs -1.3% placebo
SURMOUNT-2, 72 weeksObesity or overweight with type 2 diabetes-12.8% (10 mg), -14.7% (15 mg) vs -3.2% placebo
SURMOUNT-3, 72 weeksStarted after losing at least 5% on a 12-week intensive lifestyle program-18.4% additional (from randomization) vs +2.5% placebo

Sources: SURMOUNT-1 (PMID 35658024), SURMOUNT-1 three-year obesity and diabetes prevention analysis (PMID 39536238), SURMOUNT-2 (PMID 37385275), SURMOUNT-3 (PMID 37840095).

Key Takeaways

What We Know
  • Among adherent SURMOUNT-1 participants who lost at least 5%, 87.6% to 90.2% had reached a plateau by week 72, depending on BMI category (PMID 39800653).
  • Median time to plateau ran from 24.3 weeks (overweight) to 36.1 weeks (BMI class II and III), counted from randomization and including the dose-escalation period (PMID 39800653).
  • Staying on tirzepatide after week 36 in SURMOUNT-4 added a further 5.5% loss by week 88; switching to placebo led to 14.0% regain (PMID 38078870).
  • 89.5% of people who continued kept at least 80% of their lead-in loss, compared with 16.6% on placebo (PMID 38078870).
  • In the SURMOUNT-1 prediabetes subgroup treated for 176 weeks, mean loss at 176 weeks was 19.7% at 15 mg (PMID 39536238), close to the 20.9% reported at 72 weeks for the full trial (PMID 35658024). These are different groups, so it is not a direct comparison.
  • After withdrawal, waist circumference, blood pressure, HbA1c and non-HDL cholesterol worsened more in people who regained more weight (PMID 41284285).
What We Don't Know
  • No SURMOUNT trial tested what to do at a plateau (diet changes, training, switching drugs). The plateau analysis only described timing.
  • The "plateau" date depends on the cutoff the analysts chose (under 5% per 12 weeks). A stricter or looser cutoff would move it.
  • The plateau and long-term regain analyses (PMIDs 39800653, 42831032) were limited to adherent people who had already lost at least 5%, so they describe responders, not everyone who starts. The SURMOUNT-4 cardiometabolic analysis (PMID 41284285) looked only at people who lost at least 10% by week 36 and were then switched to placebo.
  • The 100 kcal per kg appetite figure comes from a canagliflozin study; nobody has published the equivalent number for tirzepatide.
  • Trial doses stopped at 15 mg. There is no published evidence on going beyond that to push past a plateau.
  • Trial results may not carry over to compounded or research-grade tirzepatide, whose purity and dosing are not trial-controlled.

Frequently Asked Questions

When does tirzepatide weight loss plateau?

In a post hoc analysis of SURMOUNT-1, median time to plateau was 24.3 weeks for people starting overweight, 26.0 weeks for class I obesity, and 36.1 weeks for class II and III. By week 72, roughly 88% to 90% of adherent responders had plateaued. A plateau there meant under 5% change per 12 weeks (PMID 39800653).

Does tirzepatide stop working once weight loss slows?

The trial data says no. In SURMOUNT-4, people who stayed on 10 or 15 mg after a fixed 36-week lead-in lost a further 5.5% by week 88, and 89.5% kept at least 80% of their earlier loss. Continued treatment held the earlier loss and added to it (PMID 38078870).

What happens if you stop tirzepatide?

SURMOUNT-4 switched people at a fixed week 36, not at a personal plateau. In those switched to placebo, mean weight rose 14.0% from week 36 to week 88, and only 16.6% kept at least 80% of their lead-in loss. A follow-up analysis found systolic blood pressure, waist size, HbA1c and non-HDL cholesterol worsened more in those who regained the most (PMIDs 38078870, 41284285).

Why does weight loss slow down on tirzepatide?

Part of it is the body defending its weight. A study of canagliflozin, a sodium glucose co-transporter inhibitor that causes weight loss by increasing urinary glucose excretion, used a mathematical model to estimate that appetite rises about 100 kcal per day for each kilogram lost, more than three times the drop in energy burned (PMID 27804272). How strongly that feedback acts on tirzepatide has not been measured in the SURMOUNT papers.

Does a higher tirzepatide dose delay the plateau?

In SURMOUNT-1, people on 10 or 15 mg tended to reach their plateau later than those on 5 mg, and they lost more overall: 19.5% and 20.9% at 72 weeks versus 15.0% at 5 mg (PMIDs 39800653, 35658024). That is an association across randomized dose groups. Dose changes are a decision for your prescriber.

Is some regain from my lowest weight normal on tirzepatide?

In a SURMOUNT-1 post hoc analysis of adherent people with prediabetes, mean regain from lowest weight to week 176 was 3.7 to 4.4 kg by dose. 70% regained under 5%, 22% regained 5% to under 10%, and 8% regained 10% or more, while blood sugar gains largely held (PMID 42831032).

Research-Grade Source

Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify). HighPeptides' primary vendor reference for peptides.

Browse Swiss Chems →
Code HIGHPEP10: 10% off regular-priced items

Affiliate links support HighPeptides at no extra cost.

Peer-Reviewed References

Source 1
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
Clin Obes · 2025
PMID: 39800653
Source 2
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA · 2024
PMID: 38078870
Source 3
Tirzepatide Once Weekly for the Treatment of Obesity.
N Engl J Med · 2022
PMID: 35658024
Source 4
Tirzepatide for Obesity Treatment and Diabetes Prevention.
N Engl J Med · 2025
PMID: 39536238
Source 5
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet · 2023
PMID: 37385275
Source 6
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
Nat Med · 2023
PMID: 37840095
Source 7
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
JAMA Intern Med · 2026
PMID: 41284285
Source 8
Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.
Obes Pillars · 2026
PMID: 42831032
Source 9
How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake.
Obesity (Silver Spring) · 2016
PMID: 27804272
Ebook
The Complete Peptide Protocol Guide

67-page guide: protocols, dosing, sourcing. Everything in one place.

Get the guide: $19 (normally $29) → The Peptide Buyer’s Playbook ($19) All ebooks & guides →
Disclaimer

Educational purposes only. Not medical advice.

Tirzepatide is a prescription medication. Talk to a licensed clinician before starting, stopping, or changing a dose.

📘

Get the Free 2026 Peptide Protocol Stack

Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.